课题基金 / 基金详情

HEPATIC DRUG TRANSPORTERS IN DRUG DISPOSITION

HEPATIC DRUG TRANSPORTERS IN DRUG DISPOSITION
药物处置中的肝药物转运蛋白
批准号:
6519770
负责人:
RICHARD B KIM
金额:
$17.93万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-07-01 至 2003-06-30

项目摘要

项目成果

RICHARD B KIM的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The overall objective of this application is to further our understanding of the role of carrier-mediated processes responsible for the uptake of xenobiotics from the systemic circulation into the liver -a critical first step in their hepatic elimination. A number of human hepatic basolateral membrane transporters have recently been cloned and functionally characterized with respect to the transport of endogenous compounds such as bile acids. We have cloned two novel human hepatic drug transporters with sequence homologies to the rat organic cation transporter (rOCT1), and the human organic anion transporter (hOATP). In addition, we have identified a mutation (Phe83- >Ser83)in the human hepatic sodium-dependent bile acid transporter, hNTCP, resulting from a single T->C substitution, that has a marked reduction in its transport activity. It is our hypothesis that these transport systems recognize a variety of drugs in clinical use, and that variability in function or activity has important implications in terms of drug elimination and therapy. Therefore, studies are proposed to test specific hypothesis through functional expression of individual transporters. The proposed studies in Specific Aim 1 will test the hypothesis that our newly cloned transporters, hOATP2 and hNLT, represent the biochemically characterized multispecific bile acid transporter, and a liver specific organic cation transporter, respectively. We will also define the transport kinetics of the mutant hNTCP transporter to assess whether this mutation alters substrate affinity. Additionally, the hypothesis will be tested that transport by hNTCP plays a pivotal role in the therapeutic response to tauroursodeoxycholic acid (in cholestatic liver disease) and to octreotide (in cancer chemotherapy). Specific Aim 2 focusses on site-directed mutagenesis and homologous chimera construction methods that will be used to better understand and identify key domains conferring transporter activity and substrate specificity. These studies will provide important insights regarding human hepatic drug transport systems, and enhance our understanding of the role of such processes in drug disposition.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
INTESTINAL AND HEPATIC DRUG TRANSPORTERS
  • 批准号:
    6482470
  • 项目类别:
  • 资助金额:
    $14.08万
  • 财政年份:
    2001
  • 负责人:
    RICHARD B KIM
  • 依托单位:
INTESTINAL AND HEPATIC DRUG TRANSPORTERS
  • 批准号:
    6325865
  • 项目类别:
  • 资助金额:
    $26.76万
  • 财政年份:
    2000
  • 负责人:
    RICHARD B KIM
  • 依托单位:
INTESTINAL AND HEPATIC DRUG TRANSPORTERS
  • 批准号:
    6107501
  • 项目类别:
  • 资助金额:
    $26.76万
  • 财政年份:
    1999
  • 负责人:
    RICHARD B KIM
  • 依托单位:
HEPATIC DRUG TRANSPORTERS IN DRUG DISPOSITION
  • 批准号:
    2378344
  • 项目类别:
  • 资助金额:
    $16.25万
  • 财政年份:
    1998
  • 负责人:
    RICHARD B KIM
  • 依托单位:
海外基金